Atyr Pharma
  • Pangu
  • Contact
  • Clinical Trials
  • Patients
Skip to content
  • Company
    • About Us
    • Leadership Team
    • Board of Directors
    • Advisors
    • Contact
  • Our Science
    • tRNA SYNTHETASE BIOLOGY
    • Intellectual Property
    • Publications, Posters and Presentations
  • R&D
    • Pipeline
    • Efzofitimod
    • Research Programs
    • Pangu
  • Patients
    • Clinical Trials
    • About Pulmonary Sarcoidosis
    • EFZO-FIT™
    • About SSc-ILD
    • EFZO-CONNECT™
    • Expanded Access Policy
  • Careers
    • Working at aTyr
    • Career Opportunities
  • Investors and Media
    • News Releases
    • SEC Filings
    • Stock Information
    • Events and Webcasts
    • Investor Alerts
    • Corporate Governance
    • Analyst Coverage
    • Media
© 2007 - 2025   aTyr Pharma.   Legal   Privacy Policy

The Neuropilin-2 Targeting Antibody ATYR2810 Inhibits Non-Small Cell Lung Cancer Tumor Growth in Monotherapy and Combination Therapy

American Association for Cancer Research, 2021

« A Domain-Specific Antibody to NRP2 Down-Regulated Epithelial-Mesenchymal Transition Genes and Enhanced Efficacy of Standard-of-Care Therapeutics for Aggressive Breast Cancer
ATYR2810, a Neuropilin-2 antibody, selectively blocks the NRP2/VEGFR signaling axis and sensitizes aggressive cancers to chemotherapy »
© 2007 - 2025   aTyr Pharma.   Legal   Privacy Policy
By continuing to browse this site, you agree to our use of cookies.
MENU
  • Company
    • About Us
    • Leadership Team
    • Board of Directors
    • Advisors
    • Contact
  • Our Science
    • Extracellular tRNA Synthetase Biology
    • Intellectual Property
    • Publications, Posters and Presentations
  • R&D
    • Pipeline
    • Efzofitimod
    • Research Programs
    • Pangu
  • Patients
    • Clinical Trials
    • About Pulmonary Sarcoidosis
    • EFZO-FIT™
    • About SSc-ILD
    • EFZO-CONNECT™
    • Expanded Access Policy
  • Careers
    • Working at aTyr
    • Career Opportunities
  • Investors and Media
    • Corporate Governance
      • Board of Directors
      • Board Committees
    • News Releases
    • SEC Filings
    • Stock Information
    • Analyst Coverage
    • Investor Alerts
    • Events and Webcasts
    • Media
  • Privacy Policy